Barcelona, Spain. - Treatments of malignant wounds should be designed not only to promote healing, but also to prevent and manage clinical infection, control and prevent bleeding, contain drainage from the wound, control and prevent odor, and promote the patient's comfort, according to Uwe Wollina, M.D., professor of dermatology and venerology at the Hautklinik Dresden-Friedrichstadt in Germany. Dr. Wollina spoke at the 12th Congress of the European Academy of Dermatology and Venereology in Barcelona.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.